An eventful 2023 for Sandoz saw multiple major deals and key launches, with the year culminating in the firm’s long-awaited spinoff from parent company Novartis in October.
“It’s building the plane and flying the plane at the same time.”
That was how Sandoz CEO Richard Saynor described the experience of running the world’s largest generics and biosimilars firm, while at the same time preparing for its long-awaited spinoff from
Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.
Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.
Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.
